Trial Condition(s):

N/A

Dose-escalating Phase I study to define the safety profile, pharmacokinetics, pharmacodynamics and tumor response profile of BAY 43-9006 in combination with oxaliplatin chemotherapy in patients

Bayer Identifier:

10954

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

November2002

December2007

Phase

Could I receive a placebo?

Products

Nexavar (Sorafenib, BAY43-9006)

Accepts Healthy Volunteers

Where to Participate

Locations

Locations

N/A

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

32 Years

79 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information